Champions Oncology director granted 21,216 options at $6.8
Champions Oncology (CSBR) reported an insider equity grant on a Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Champions Oncology (CSBR) reported an insider equity grant on a Form 4. Director David Sidransky was awarded an option to purchase 21,216 shares on 11/05/2025 at an exercise price of $6.8 per share, expiring on 11/05/2035.
The filing lists the transaction code as A (grant). The option was acquired in direct ownership. Vesting is scheduled over twelve months, with tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. The option is exercisable over a ten‑year period.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to purchase Common Stock | 21,216 | $6.80 | $144K |
Footnotes (1)
- F1. The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CSBR disclose in this Form 4?
Who is the reporting person in the CSBR Form 4?
What is the exercise price and expiration of the option?
What is the vesting schedule for the CSBR option grant?
What transaction code and ownership form are indicated?
AI-generated analysis. How Rhea-AI works. Not financial advice.